TITLE

MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease

AUTHOR(S)
Kordelas, L; Rebmann, V; Ludwig, A-K; Radtke, S; Ruesing, J; Doeppner, T R; Epple, M; Horn, P A; Beelen, D W; Giebel, B
PUB. DATE
April 2014
SOURCE
Leukemia (08876924);Apr2014, Vol. 28 Issue 4, p970
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A letter to the editor is presented concerning a study which examines mesenchymal stem cells (MSCs)-derived exosomes as treatment for refractory graft-versus-host disease (GvHD).
ACCESSION #
95485681

 

Related Articles

  • Oral Session 32 (Plaza Ballroom): Therapy-Stem Cells.  // Journal of Extracellular Vesicles;2013, Vol. 2, p137 

    The article presents abstracts on topics related to therapy/stem cells which include biochemical potential of mesenchymal stem cell (MSC) exosomes, effectiveness of membrane TRAIL-armed exosomes as an anti-tumor therapy, and role of mesenchymal stem-cell derived exosomes on the treatment of...

  • Decidual Stromal Cells from Placenta - Experimental and Clinical Studies. Ringdén, O.; Kaipe, H.; Erkers, T.; Nava, S.; Molldén, P.; Sadeghi, B. // Cell Journal (Yakhteh);Summer 2013 Supplement 1, Vol. 15 Issue Sup 1, p13 

    Objective: One of the most serious complications after hematopoietic stem cell transplantation is acute graftversus- host disease (GVHD), which develops when donor- derived T-cells recognize and become activated by alloreactive recipient tissue. We were the first to use bone marrow-derived...

  • Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. Dander, E; Lucchini, G; Vinci, P; Introna, M; Masciocchi, F; Perseghin, P; Balduzzi, A; Bonanomi, S; Longoni, D; Gaipa, G; Belotti, D; Parma, M; Algarotti, A; Capelli, C; Golay, J; Rovelli, A; Rambaldi, A; Biondi, A; Biagi, E; D'Amico, G // Leukemia (08876924);Jul2012, Vol. 26 Issue 7, p1681 

    The article presents a study which examines the biological effect of mesenchymal stromal cells (MSCs) on the treatment of graft-versus-host disease (GvHD). The study was participated by 10 patients with post-transplant GvHD who were managed with multiple infusions of third-party bone...

  • Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease. Kyoung-Woon Kim; Su-Jin Moon; Min-Jung Park; Bo-Mi Kim; Eun-Kyung Kim; Sung-Hee Lee; Eun-Jung Lee; Byung-Ha Chung; Chul-Woo Yang; Mi-La Cho // Stem Cell Research & Therapy;10/23/2015, Vol. 6, p1 

    Introduction: Mesenchymal stem cells (MSCs) can protect bone marrow transplantation (BMT) recipients from the lethal acute graft-versus-host disease (aGVHD) development. However, the mechanisms underlying the anti-inflammatory properties of MSCs in aGVHD remain to be elucidated. The...

  • Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. Hyeon Gyu Yi; Seung-Ah Yahng; Inho Kim; Je-Hwan Lee; Chang-Ki Min; Jun Hyung Kim; Chul Soo Kim; Sun U. Song // Korean Journal of Physiology & Pharmacology;2016, Vol. 20 Issue 1, p63 

    Severe graft-versus-host disease (GVHD) is an often lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT). The safety of clinicalgrade mesenchymal stem cells (MSCs) has been validated, but mixed results have been obtained due to heterogeneity of the MSCs. In this phase...

  • Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Peng, Y; Chen, X; Liu, Q; Zhang, X; Huang, K; Liu, L; Li, H; Zhou, M; Huang, F; Fan, Z; Sun, J; Ke, M; Li, X; Zhang, Q; Xiang, A P // Leukemia (08876924);Mar2015, Vol. 29 Issue 3, p636 

    Refractory chronic graft-versus-host disease (cGVHD) is a significant complication resulting from allogeneic hematopoietic stem cell transplantation (HSCT). Mesenchymal stromal cells (MSCs) have shown promise for treating refractory cGVHD, but the favorable effects of MSCs therapy in cGVHD are...

  • CCR7 Expressing Mesenchymal Stem Cells Potently Inhibit Graft-versus-Host Disease by Spoiling the Fourth Supplemental Billingham’s Tenet. Li, Hong; Jiang, Yan-Ming; Sun, Yan-Feng; Li, Ping; Dang, Rui-Jie; Ning, Hong-Mei; Li, Yu-Hang; Zhang, Ying-Jie; Jiang, Xiao-Xia; Guo, Xi-Min; Wen, Ning; Han, Yan; Mao, Ning; Chen, Hu; Zhang, Yi // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    The clinical acute graft-versus-host disease (GvHD)-therapy of mesenchymal stem cells (MSCs) is not as satisfactory as expected. Secondary lymphoid organs (SLOs) are the major niches serve to initiate immune responses or induce tolerance. Our previous study showed that CCR7 guide murine MSC line...

  • Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Kim, Nayoun; Im, Keon-Il; Lim, Jung-Yeon; Jeon, Eun-Joo; Nam, Young-Sun; Kim, Eun-Jung; Cho, Seok-Goo // Annals of Hematology;Oct2013, Vol. 92 Issue 10, p1295 

    Mesenchymal stem cells (MSCs) have emerged as a therapeutic approach in a range of medical fields, including regenerative medicine, cancer, autoimmune diseases, and inflammatory diseases, because of their unique properties of tissue repair and major histocompatibility complex-unmatched...

  • AlloCure Raises $25 Mln Series B Venture Financing.  // Biomedical Market Newsletter;4/7/2012, Vol. 21, p1 

    The article discusses the closing of a 25 million dollars series B venture financing by the AlloCure Inc. It states that the managing partner of Lundbeckfond Ventures Mette Kirstine Agger has joined the Allocure board of directors. It further informs that the company is working on developing an...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics